What is Prazer Therapeutics?
Prazer Therapeutics is a biotechnology enterprise dedicated to the development of novel therapeutics for intractable diseases. At the core of its technological advantage is the SPiDEM platform, a next-generation targeted protein degradation (TPD) system designed to overcome the limitations of existing modalities. By utilizing rational drug design, the company addresses critical unmet needs in neurodegenerative disorders, oncology, and inflammatory conditions. Furthermore, the firm maintains a robust pipeline of anti-viral candidates, specifically targeting chronic hepatitis B and acute respiratory inflammation caused by various viral pathogens. Through its focus on superior pharmacokinetics and efficacy, Prazer Therapeutics is establishing itself as a leader in the next wave of precision medicine.
How much funding has Prazer Therapeutics raised?
Prazer Therapeutics has raised a total of $19.6M across 1 funding round:
Series B
$19.6M
Series B (2025): $19.6M with participation from STIC Ventures, Mirae Asset Capital, and K2 Investment Partners
Key Investors in Prazer Therapeutics
STIC Ventures
A prominent venture capital firm based in Asia that focuses on fostering economic growth by investing in high-potential companies across diverse sectors.
Mirae Asset Capital
A Seoul-based investment banking and capital management firm known for its strategic participation in growth-stage ventures and financial services.
K2 Investment Partners
A specialized investment firm focused on growth-stage venture capital, providing sophisticated deal sourcing and risk-adjusted returns in the biotechnology and software sectors.
What's next for Prazer Therapeutics?
With the successful closure of this funding round, Prazer Therapeutics is poised to advance its lead candidates through rigorous clinical trials and regulatory milestones. The strategic allocation of these funds will likely prioritize the expansion of the SPiDEM platform's utility, potentially unlocking new therapeutic targets that were previously considered undruggable. As the company moves forward, stakeholders can expect a heightened focus on data-driven clinical validation and potential strategic partnerships to facilitate the commercialization of its anti-viral and oncology assets. The firm's ability to maintain a competitive edge in the TPD space will be instrumental in its long-term growth and its mission to deliver transformative patient outcomes.
See full Prazer Therapeutics company page
